Artivion Q4 Revenue $116M Up 19.2% but Misses Estimates
Artivion posted fourth quarter 2025 revenue of $116 million, up 19.2% year-on-year but 0.8% below consensus. Non-GAAP EPS of $0.17 matched forecasts, and FY2026 adjusted EBITDA guidance of $107.5 million at midpoint modestly exceeded analysts’ estimates.
1. Q4 2025 Financial Results
Artivion reported fourth quarter 2025 revenue of $116 million, a 19.2% increase from the same period a year earlier but 0.8% below the $117 million consensus. Non-GAAP EPS was $0.17, in line with expectations, and adjusted EBITDA reached $22.7 million, reflecting a 19.6% margin.
2. FY2026 Guidance
The company guided FY2026 adjusted EBITDA to $107.5 million at the midpoint, surpassing the $106.5 million analyst estimate, and set full-year revenue guidance midpoint at $495 million, about 1% above consensus forecasts.
3. Segment Performance Drivers
In Q4, stent graft sales jumped 44% year-on-year, On-X product revenue climbed 25%, and preservation services grew 6%, underpinned by strong demand across its aortic device portfolio and continued R&D progress.
4. Operational and Cash Flow Metrics
Operating margin expanded to 9.2% from 2.7% a year ago, while free cash flow swung to –$7.95 million versus positive $8.71 million last year, reflecting increased investment in product development and working capital shifts.